• Michael Yee from UBS set a price target of $60 for NASDAQ:SRRK, indicating a potential increase of approximately 45.24%.
• The average 12-month price target among analysts is $48.9, with Barclays raising its target to $52.
• Despite a recent 3.39% decrease, analyst ratings such as "overweight" from Cantor Fitzgerald and "outperform" from Wolfe Research show strong confidence in the stock's future performance.

Scholar Rock Holding Corporation, trading on NASDAQ under the symbol SRRK, is a biopharmaceutical company focused on developing innovative treatments for serious diseases. The company has garnered attention from analysts and investors alike, with a consensus recommendation of "Buy" from sixteen brokerages. This includes one sell recommendation, eleven buy recommendations, and four strong buy recommendations.

On January 7, 2026, Michael Yee from UBS set a price target of $60 for SRRK, suggesting a potential price increase of approximately 45.24% from its current price of $41.31. This optimistic outlook is supported by other analysts, with an average 12-month price target of $48.9. Barclays has also increased its price target from $45 to $52, maintaining an "overweight" rating.

Cantor Fitzgerald reiterated an "overweight" rating for Scholar Rock on December 11th, while Wolfe Research began coverage on November 18th with an "outperform" rating and a price target of $42. Despite the stock's recent 3.39% decrease, these ratings indicate strong confidence in the company's future performance.

The stock has experienced fluctuations, with a low of $41.19 and a high of $43.06 in recent trading. Over the past year, SRRK has reached a high of $48.28 and a low of $22.71. The company's market capitalization is approximately $4.21 billion, with a trading volume of 707,076 shares, reflecting active investor interest.